Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab or Glofitamab After CAR-T in Relapsed/Refractory DLBCL
NCT04889716Phase 2Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Nov 2021
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab, glofitamab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Abramson Cancer Center. Started Nov 2021; status: active, not recruiting.
02
Drugs
mosunetuzumabglofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04889716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889716.